CEL SCI CORP (NASDAQ:CVM) saw an insider transaction reported on May 13, 2026, involving the company's Chief Executive Officer, Geert R. Kersten. Mr. Kersten acquired a total of 100,000 shares of the firm’s common stock. The purchase was executed at a price point of $1.19 per share, resulting in an aggregate investment value of $119,000.
This reported insider buying comes against a backdrop of significant volatility for the stock. At the time of this transaction, the shares were trading close to their 52-week low of $0.89. Furthermore, the stock had seen a notable decline over the preceding week, dropping by 25%, and experienced an even steeper decrease of 83% over the past year.
According to documentation related to the filing, Mr. Kersten purchased these shares as restricted stock directly from CEL SCI CORP. The $1.19 per share purchase price was anchored to the closing price recorded on May 12, 2026, which was identified as the most recent available closing figure at the moment of the transaction.
Following this specific acquisition, Mr. Kersten's direct holdings in CEL SCI CORP common stock increased to 222,497 shares. An analysis provided by InvestingPro suggests that, based on current levels, the stock appears undervalued. Subscribers to InvestingPro have access to thirteen additional ProTips concerning the company.
Beyond this insider activity, CEL-SCI Corporation has been executing several other financial and commercial initiatives. The company recently completed a public offering involving 6,000,000 shares of common stock, which was sold at $1.20 per share. This transaction generated gross proceeds amounting to approximately $7.2 million. ThinkEquity served as the sole placement agent for this recent offering.
This latest capital raise followed an earlier announcement from CEL-SCI regarding the pricing structure of the offering, which had been anticipated to generate similar total gross proceeds before deducting various fees and expenses.
Moreover, CEL-SCI has also solidified a strategic partnership by entering into a distribution agreement with Amarox. This agreement covers the company's Multikine product within Saudi Arabia. The terms of this arrangement include a 50-50 revenue-sharing model, contingent upon receiving Breakthrough Medicine Designation from the Saudi Food and Drug Authority (SFDA). Under the structure of this partnership, Amarox is responsible for managing local regulatory affairs and handling communication with the SFDA.
These cumulative developments - including the CEO's purchase, the successful public offering, and the international distribution agreement - collectively highlight CEL-SCI’s ongoing efforts to expand both its financial capitalization and its commercial footprint in various markets. The insider buying may be viewed as an indicator of internal confidence despite the stock's recent price weakness.